59 results about "Skeletal Muscle Tissue" patented technology

The invention discloses an application of ganoderma lucidum spore oil in preparation of a medicine or health food for improving sarcopenia. Ganoderma lucidum spore oil can effectively improve weight loss and muscle hypofunction induced by glucocorticoid, and improve the holding power and exercise tolerance level of the body; meanwhile, the skeletal muscle mass and the muscle fiber cross sectional area can be increased, and the skeletal muscle tissue morphological structure is improved; in addition, the ganoderma lucidum spore oil can improve the oxidation resistance of the body and skeletal muscle and reduce the oxidative stress level, so that the skeletal muscle injury related to aging is relieved on the whole. Therefore, the ganoderma lucidum spore oil has a definite application value in the aspect of improving the skeletal muscle function.

The invention relates to the technical field of biology, in particular to a composition for preparing organoids and application of the composition. The invention discloses a construction method of a multi-tissue co-differentiation organoid. Based on the method, different stem cells (such as ESCs and iPSCs) can be utilized to stably construct a three-dimensional model for simulating interaction of nerves, muscles and bones. According to the method, the complex operation of separately differentiating multiple tissues and integrating the multiple tissues is avoided, particularly the problem that bone tissues and skeletal muscle tissues are difficult to fuse with other tissues is solved, a co-development regulation mechanism of the multiple tissues can be displayed in vitro, and a convenient supporting platform is provided for researches such as drug discovery.

A method of treating injured skeletal muscle tissue generally includes applying to injured skeletal muscle tissue a therapeutic composition that includes a purified exosome product (PEP) and a pharmaceutically acceptable carrier. In one or more embodiments, the method includes applying from 1×1011 PEP exosomes to 1×1013 PEP exosomes to the injured skeletal muscle. In one or more embodiments, the therapeutic composition further includes a supportive matrix such as a collagen scaffold, a tissue sealant, fibrin glue, or a hydrogel.

The invention discloses application of hydrogen-rich water in preparation of a drug for treating Duchenne type muscular dystrophy, and particularly relates to the technical field of medicines.The random control experiment is adopted, homologous c57 mice serve as a normal control group, mdx mice are randomly divided into a model group and a hydrogen-rich water group, and the exercise ability is evaluated through a four-limb holding power test and a rotating bar test; detecting mouse creatine kinase by an enzyme-linked immunosorbent assay; carrying out hematoxylin-eosin, NADH-tetrazole reductase and improved Goori three-color dyeing, and carrying out cytochrome C oxidase, succinate dehydrogenase and SDH-COX combined dyeing to observe the pathological change of the skeletal muscle tissue; the invention discloses that the muscle injury condition of a Duchenne type muscular dystrophy model mouse is improved by the hydrogen-rich water through a mitochondrial protection mechanism, and the hydrogen-rich water has a relatively high application prospect and a relatively high economic value.

To provide methods for producing an artificial skeletal muscle tissue from pluripotent stem cells.SOLUTION: The present invention describes a method for preparing an engineered skeletal muscle tissue, as well as skeletal myoblasts, skeletal myotubes, and satellite cells, a medium used being serum-free and different chemicals and their concentrations, as well as the physical stimuli, being defined. Additionally, the methods described herein are performed without transfection of human cells with transgenes. The engineered skeletal muscle cells exhibit myoblast-, myotube-, or satellite cell-specific genetic markers, demonstrating efficient differentiation of these cell types. Despite its engineered production, the skeletal muscle tissue possesses excellent stimulus-dependent contractility and exhibits contractions in response to different stimulation frequencies.SELECTED DRAWING: None

The invention discloses a method for separating, identifying and proliferating myoblasts of small-tailed han sheep, which comprises the following steps: (1) taking and treating skeletal muscle tissues: selecting healthy small-tailed han sheep, collecting the skeletal muscle tissues under sterile conditions, washing and cutting into pieces to obtain tissue blocks; (2) primary myoblast isolated culture: digesting, filtering and centrifuging the obtained tissue block, and culturing; (3) myoblast purification: purifying the cultured primary myoblasts to obtain purified myoblasts; (4) identifying myoblasts: identifying the obtained purified myoblasts; and (5) proliferation of myoblasts: after identification is completed, carrying out cell proliferation on the purified myoblasts obtained in the step (3) by utilizing a proliferation culture medium containing vitamin E. According to the method provided by the invention, high-purity and high-activity myoblasts can be obtained; vitamin E is utilized, so that the proliferation capacity of myoblasts can be remarkably improved, and the cell differentiation function of the myoblasts is not influenced.

A device includes a first unit for skeletal muscle tissue formation; a second unit for motor neuron culture; a third unit for causing the first and second units to communicate with each other; and a pillar serving as a scaffold for skeletal muscle tissue formation. The first unit includes a first base material and a first culture tank formed in the first base material. The second unit includes a second base material and a second culture tank formed in the second base material. The third unit includes a third base material and an axon channel formed in the third base material, through which a bundle of axons passes. One end of the third unit is connectable to the second unit and cause the axon channel and the second culture tank to communicate with each other. A first opening part is formed to the other end of the third unit.

The invention discloses a space transcriptome technology-based white feather broiler skeletal muscle fiber heterogeneity analysis method. The method comprises the following steps: preparing a white feather broiler skeletal muscle tissue embedding sample; the skeletal muscle tissue embedded sample obtained in the step 1 is sliced, and part of the sliced sample is dyed and then photographed; carrying out space transcriptome library construction on partial slice samples, and finally sequencing and carrying out data analysis. A space transcriptome technology is utilized to construct a space transcriptome map of four skeletal muscles of the white feather broiler chicken, the heterogeneity of the skeletal muscle muscle fibers of the white feather broiler chicken is revealed, and the space distribution of I-type and II-type muscle fibers of four skeletal muscle tissues of lumbar muscle, semimembrane muscle, soleus muscle and gastrocnemius muscle is verified; the functional difference between the I-type muscle fiber gene and the II-type muscle fiber gene is proved, and a new detailed skeletal muscle muscle fiber heterogeneity data support is provided for chicken breed improvement.

The invention also discloses application of the bovine-derived SYPL2 gene in regulation and control of animal muscle development and regeneration. According to the invention, the SYPL2 gene is found to be a key regulatory factor for muscle development, and an intervention strategy based on the gene is developed, so that a part of technical problems are effectively solved, and an innovative solution is provided for livestock breeding and muscle regeneration medicine. The invention discovers that the SYPL2 gene has high specific expression in bovine skeletal muscle tissues for the first time, and has the capability of promoting proliferation and differentiation of bovine myoblasts cultured in vitro. More importantly, when the bovine SYPL2 gene overexpression plasmid is locally injected into a mouse with acute muscle injury, a remarkable muscle injury regeneration and repair treatment effect is shown, so that a brand new target and a solution are provided for livestock molecular breeding and muscle regeneration medicine; and an important basis is provided for improving the production efficiency of animal husbandry and developing a novel muscle repair therapy.

The application relates to the technical field of animal nutrition and meat quality regulation, and particularly relates to application of vascular endothelial growth factor B (VEGF-B) in increasing intramuscular fat content of pigs. The content of VEGF-B in pig serum and the expression level of VEGF-B in skeletal muscle tissue are significantly positively correlated with the intramuscular fat content of pigs, so that VEGF-B can be used as a biomarker for predicting the intramuscular fat content of pigs; meanwhile, fish oil rich in n-3 polyunsaturated fatty acids can promote the expression level of VEGF-B by activating G protein-coupled receptor 120 (GPR120), then increase the transvascular endothelial transport of fatty acids in blood vessels to skeletal muscle, and finally increase the intramuscular fat content.

The invention relates to the technical field of small nucleic acid drug targeted delivery, and particularly provides an oligonucleotide delivery ligand compound, a conjugate and application thereof. The ligand compound provided by the invention has the effect of improving the delivery capacity of oligonucleotide in extrahepatic tissues such as eye tissues, adipose tissues, nervous tissues and skeletal muscle tissues, and can effectively deliver siRNA drugs to target tissues; it is helpful to alleviate, prevent and / or treat pathological conditions or diseases caused by abnormal expression of specific genes in tissue cells.

The invention provides a method for constructing a podocyte injury animal model, and belongs to the technical field of experimental animal models. The method specifically comprises the following steps: injecting miR-1 agomir twice a week through caudal veins of a male C57BL / 6 mouse for 7 times in total to obtain a podocyte injury animal model; the miR-1 with high expression of skeletal muscle tissue is used for inducing podocyte damage, interference of damage of other organs and cells is reduced, and the miR-1 plays an important role in research on pathogenesis of chronic kidney diseases.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an Androgen Receptor (AR) gene. The AR RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an AR gene. Pharmaceutical compositions that include one or more AR RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described AR RNAi agents to central nervous system (CNS) tissue and / or skeletal muscle tissue, in vivo, provides for inhibition of AR gene expression and a reduction in AR activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including spinal and bulbar muscular atrophy (SBMA).

This invention discloses the application of rilpivirine (RPV) in the preparation of drugs for the prevention and treatment of trichinosis. This invention belongs to the field of biomedical technology. A mouse model of trichinosis was established by oral feeding. After oral administration of rilpivirine, the number of larval cysts, histopathological changes, and ultrastructural changes in the skeletal muscle tissue of the trichinella-infected mouse model were observed. The results showed that rilpivirine (as shown in Formula I) has a significant effect in killing trichinella larval cysts and can improve the degree of muscle tissue fibrosis caused by trichinosis. This invention provides a new technical means for the treatment of trichinosis and will also give rilpivirine broad application prospects in the treatment of fibrosis-related diseases caused by parasitic infections.

The invention discloses a lactobacillus rhamnosus CQFP202457 and application of the lactobacillus rhamnosus CQFP202457 and ellagic acid in relieving exercise fatigue, and belongs to the technical field of microorganisms. The preservation number of the lactobacillus rhamnosus CQFP202457 is CGMCC (China General Microbiological Culture Collection Center) No. 29784. The composition provided by the invention contains ellagic acid and lactobacillus rhamnosus CQFP202457, and can significantly prolong the exercise exhaustion time, reduce the content of fatigue-related metabolites in serum, improve the total antioxidant ability of serum, liver and skeletal muscle and the antioxidant enzyme gene expression level, and improve the exercise-induced liver and skeletal muscle tissue damage. The strain and the composition thereof provided by the invention can be used as exercise synbiotics for preparing products for relieving exercise-induced fatigue, improving exercise performance, reducing exercise-induced oxidative stress or relieving exercise-induced muscle injury.

This invention is in the field of artificial skeletal muscle. The present invention relates to a method for producing artificial skeletal muscle tissue from pluripotent stem cells, comprising five defined steps, whereby contractile artificial skeletal muscle tissue is produced, and the method is characterized in that steps (i) - (iii) are carried out in a bioreactor under suitable conditions, and wherein the method does not include the use of a solubilized basement membrane preparation extracted from Engelbreth-Holm swarm mouse sarcoma.Furthermore, an artificial skeletal muscle tissue is disclosed, obtainable by a method disclosed herein, wherein the artificial skeletal muscle tissue generates a contraction force of at least 0.5 millinewtons (mN) upon stimulation of 1 Hz to 150 Hz, wherein the artificial skeletal muscle tissue is serum-free, and wherein the artificial skeletal muscle tissue does not include a transgene. Medical and non-medical uses of the artificial skeletal muscle tissue are also described.

The invention discloses an application of rilpivirine (RPV) in preparation of a medicine for preventing and treating trichinosis, and particularly discloses an application of rilpivirine (RPV) in preparation of a medicine for preventing and treating trichinosis. The invention belongs to the technical field of biological medicine. According to the present invention, the trichinellosis mouse model is constructed by using the oral feeding method, such that the trichinellosis mouse model is constructed, after rilpivirine is orally taken, the number of larva sacs in skeletal muscle tissues of the trichina-infected mouse model, histopathology, ultrastructure change and the like are observed. Results show that rilpivirine (as shown in the formula I) has a remarkable effect of killing trichina larva cysts and can improve the degree of muscle tissue fibrosis caused by trichinosis. The invention provides a new technical means for treating trichinosis, and rilpivirine has a wide application prospect in the aspect of treating fibrosis-related diseases caused by parasitic infection. # imgabs0 #

The present invention provides double stranded ribonucleic acid (dsRNA) agents for inhibiting expression of a target gene, comprising an antisense strand which is complementary to the target gene; a sense strand which is complementary to the antisense strand and forms a double stranded region with the antisense strand; and at least one alpha-v-beta-6 (αvβ6) integrin targeting ligand that mediates delivery to an extrahepatic tissues, e.g., muscle tissue, e.g., skeletal muscle tissue and / or cardiac muscle tissue, or lung tissue, conjugated to at least one strand, compositions comprising such dsRNA agents, and methods of use thereof for treating a subject having a disorder that would benefit from reduction in expression of the target gene. The dsRNA may optionally contain an in vivo delivery enhancing agent.

The invention discloses an application of a KLF9 gene in chicken heat stress resistance breeding. The invention also discloses an interference fragment of the KLF9 gene, a primer pair based on the interference fragment of the KLF9 gene, an interference vector containing the interference fragment and a construction method of the interference vector. The invention also discloses a detection kit. The invention also discloses an interference fragment of the KLF9 gene, a primer pair based on the interference fragment of the KLF9 gene, and an application of the interference vector in chicken heat stress resistance breeding. The invention further discloses a breeding method of the heat stress resistant chicken. The gene KLF9 provided by the invention can be used as a marker for detecting the heat stress resistance level of the chicken, the expression quantity of the gene can be quickly judged by detecting the expression quantity of the gene in the skeletal muscle of the chicken in breeding, the chicken with a half-sib relationship with a detected individual can be selected and remained, and the quick breeding of target characters in the chicken breeding process can be accelerated. The primer pair and the kit provided by the invention can be used for detecting the expression quantity of the KLF9 in the chicken skeletal muscle tissue, and the detection method is simple and rapid.

In one embodiment, the invention provides a dual-cassette gene vehicle comprising cassettes for expression of both a mini-dystrophin gene and NF-κB / p65-shRNA gene in cardiac muscle tissue and skeletal muscle tissue, which is an adeno-associated viral (AAV) vector, wherein the mini-dystrophin gene is operably linked to a construct comprising a muscle-specific first promoter and a modified Mcken (MCK) enhancer and wherein the NF-κB / p65-shRNA gene is under the control of a second promoter. Also are provided pharmaceutical compositions comprising such gene vehicles and a method for ameliorating Duchenne muscular dystrophy (DMD) employing such gene delivery vehicles and pharmaceutical compositions.

The invention provides a transferrin receptor (TfR1) antibody for conjugation to therapeutic payloads. The TfR1 antibodies may be used for delivering the therapeutic payloads, for instance oligonucleotide-based agents, to CNS tissues, skeletal muscle tissues, or heart tissues in vivo.

The invention relates to novel application of ergothioneine, in particular to application of ergothioneine in preparation of a preparation for assisting in relieving exercise-induced fatigue. It is found that ergothioneine has a very remarkable effect on assisting in relieving exercise-induced fatigue, and particularly, ergothioneine can enhance the exercise tolerance of the body, improve the removal efficiency of metabolic waste generated by exercise, relieve skeletal muscle tissue damage, improve oxidative stress damage of the body and improve the inflammatory state of the body. The ergothioneine is used for preparing products with related effects and has an application prospect.

The invention provides a large white pig skeletal muscle fiber space transcriptional map and an acquisition method thereof, and the space transcriptional map shows that the proportions of STI type and STII type muscle fibers in lumbar major muscles are respectively about 34% and 66%, the proportions of STI type and STII type muscle fibers in semi-membrane muscles are respectively about 11% and 89%, the proportions of STI type and STII type muscle fibers in flatfish muscles are respectively about 14% and 66%, and the proportions of STI type and STII type muscle fibers in flatfish muscles are respectively about 14% and 66%. The proportions of STI-type muscle fibers and STII-type muscle fibers in gastrocnemius muscle are respectively about 27% and 73%, and two subtypes of STII-type muscle fibers of four skeletal muscles are different. The spatial distribution of I-type, IIA-type and IIB-type muscle fibers of four skeletal muscle tissues of a large white pig is displayed, functional difference of I-type, IIA-type and IIB-type muscle fiber genes is proved, and detailed skeletal muscle fiber heterogeneity data support is provided for pig variety improvement.

Anelloviridae family vectors (e.g., anellovectors) can be used to deliver various therapeutic effectors to desired tissues in a subject, such as liver tissue, kidney tissue, spleen tissue, ovary tissue, lymph node tissue, skeletal muscle tissue, lung tissue, or bone marrow tissue. In some embodiments, the anellovectors do not substantially target heart tissue. In some embodiments, anellovectors can be used to deliver a chimeric antigen receptor (CAR) to a tissue comprising T cells, for example, in the spleen.

The invention provides a transferrin receptor (TfR1) antibody for conjugation to therapeutic payloads. The TfR1 antibodies may be used for delivering the therapeutic payloads, for instance oligonucleotide-based agents, to CNS tissues, skeletal muscle tissues, or heart tissues in vivo.

Provided are a modified nucleoside, a use and method for using the nucleoside to prepare an RNAi preparation for extrahepatic delivery, and an RNAi preparation for extrahepatic delivery obtained thereby. The RNAi preparation can effectively deliver RNAi to extrahepatic tissue, such as muscle tissue, like skeletal muscle tissue and myocardial tissue, and adipose tissue.

The invention discloses a specific skeletal muscle cell targeting liposome and a preparation method thereof, and belongs to the technical field of skeletal muscle tissue targeting. The lipidosome specifically targeting the skeletal muscle cells comprises a lipidosome body, and the surface of the lipidosome body is modified with a peptide fragment specifically bound by polyethylene glycol-amino acid containing an acidic side chain and biotin-streptavidin-laminin. The lipidosome for specifically targeting the skeletal muscle cells can be enriched at skeletal muscle tissues, and the coated recombinant adeno-associated virus can be efficiently released around the skeletal muscle cells.

The present disclosure provides calcium voltage-gated channel accessory subunit gamma 1 (CACNG1) antigen binding proteins and protein-drug conjugates comprising the CACNG1 antigen binding protein conjugated to a molecular cargo (e.g., a polynucleotide molecule, a polypeptide molecule, a carrier, or a small molecule) for delivery of the molecular cargo to skeletal muscle tissue and / or cells. Methods for treating, preventing, or reducing the likelihood of various skeletal muscle diseases and / or disorders using such antigen binding proteins or protein-drug conjugates are also provided.

The invention relates to the technical field of biology, in particular to application of exercise-induced fatigue in regulation and control of exosome miRNA expression and reverse regulation and control of exosome miRNA expression through resveratrol. According to the application of exercise-induced fatigue in regulation and control of exosome miRNA expression, the exercise-induced fatigue causes exosome miRNA differential expression of cells and tissues. The invention relates to application of resveratrol in reversing exosome miRNA differential expression of cells and tissues caused by exercise-induced fatigue. Exercise-induced fatigue can cause differential expression of exosome miRNA of primary myocardial cells, skeletal muscle cells and liver cells and differential expression of exosome miRNA of mouse myocardial tissues, skeletal muscle tissues and liver tissues, and resveratrol can reverse exosome miRNA differential expression caused by exercise-induced fatigue.

The invention provides a transferrin receptor (TfR1) antibody for conjugation to therapeutic payloads. The TfR1 antibodies may be used for delivering the therapeutic payloads, for instance oligonucleotide-based agents, to CNS tissues, skeletal muscle tissues, or heart tissues in vivo.